Q-omics provides the consensus-scored IQCA1 profile across patient tissues and cancer cell-line models. IQCA1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, IQCA1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, IQCA1 RNA expression shows 18,188 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KICH, and THYM as cancer lineages where IQCA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IQCA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IQCA1 survival associations across molecular data types. IQCA1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IQCA1 RNA expression–survival associations across cancer types. High IQCA1 expression shows unfavorable associations in STAD, ACC, LIHC and HNSC, but favorable associations in KIRC and KIRP. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for IQCA1 RNA expression.
This table summarizes IQCA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for IQCA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IQCA1 shows lower tumor expression in KICH, KIRC, LUAD and THCA and higher tumor expression in HNSC and COAD. The KICH box plot shows higher IQCA1 RNA expression in normal versus tumor tissue (log2 FC = −3.266, t-test p < 0.001).
This table shows molecular features associated with IQCA1 in patient tissues and cancer cell lines. In patient samples, IQCA1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IQCA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
